Lung Function and Asthma Clinical Control in N-ERD Patients, Three-Year Follow-Up in the Context of Real-World Evidence
Gandhi Fernando Pavón-Romero,1 Ramcés Falfán-Valencia,2 Katia Vanessa Gutiérrez-Quiroz,1 Estivaliz Arizel De La O-Espinoza,1 Nancy Haydée Serrano-Pérez,1 Fernando Ramírez-Jiménez,1 Luis M Teran1 1Department of Immunogenetics and Allergy, Instituto Nacional de Enfermedades Respiratorias, Mexico City,...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-09-01
|
| Series: | Journal of Asthma and Allergy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/lung-function-and-asthma-clinical-control-in-n-erd-patients-three-year-peer-reviewed-fulltext-article-JAA |
| _version_ | 1797690477505413120 |
|---|---|
| author | Pavón-Romero GF Falfán-Valencia R Gutiérrez-Quiroz KV De La O-Espinoza EA Serrano-Pérez NH Ramírez-Jiménez F Teran LM |
| author_facet | Pavón-Romero GF Falfán-Valencia R Gutiérrez-Quiroz KV De La O-Espinoza EA Serrano-Pérez NH Ramírez-Jiménez F Teran LM |
| author_sort | Pavón-Romero GF |
| collection | DOAJ |
| description | Gandhi Fernando Pavón-Romero,1 Ramcés Falfán-Valencia,2 Katia Vanessa Gutiérrez-Quiroz,1 Estivaliz Arizel De La O-Espinoza,1 Nancy Haydée Serrano-Pérez,1 Fernando Ramírez-Jiménez,1 Luis M Teran1 1Department of Immunogenetics and Allergy, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; 2Laboratory of Human Leukocyte Antigen, Instituto Nacional de Enfermedades Respiratorias, Mexico City, MexicoCorrespondence: Luis M Teran, Department of Immunogenetics and Allergy, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Tlalpan, Mexico City, 14080, Mexico, Tel +52 5557481700 exr. 5162, Email teranjlm@gmail.comPurpose: To describe the lung function and clinical control of asthma in patients with N-ERD during three years of medical follow-up using GINA guidelines.Methods: We evaluated 75 N-ERD and 68 asthma patients (AG). Clinical control, lung function, and asthma treatment were evaluated according to GINA-2014. We compared all variables at baseline and one, two, and three years after treatment.Results: At baseline, the N-ERD group had better basal lung function (LF) than the AG group (p< 0.01), and the AG group used higher doses of inhaled corticosteroids than the N-ERD group (52.4% vs 30.5%, p=0.01) and short-term oral corticosteroid (OCS) use (52.4% vs 30.5%, p< 0.01). Instead, N-ERD patients needed more use of leukotriene receptor antagonists (LTRA) (29.3% vs 5.9%, p< 0.01). This group had better clinical control than the AG group (62.1% vs 34.1%, p< 0.01). During the medical follow-up, the LF of the N-ERD group remained at normal values; however, these parameters improved in AG from one year (p< 0.01). Likewise, there was a diminished use of high doses of ICS (52.4% vs 33%, p< 0.05) and short-term OCS (67.6% vs 20.6%, p< 0.01) in asthma patients. However, N-ERD patients still needed more use of LTRAs (p< 0.02) during the study. In this context, one-third of N-ERD patients had to use a combination of two drugs to maintain this control. From the second year on, clinical control of asthma was similar in both groups (p> 0.05).Conclusion: According to GINA guidelines, only one-third of patients with N-ERD can gradually achieve adequate lung function and good asthma control with a high ICS dosage. Only a very small portion of patients will require the continued use of a second medication as an LTRA to keep their asthma under control.Keywords: N-ERD, asthma, severe asthma, corticosteroids, GINA guidelines, asthma clinical control |
| first_indexed | 2024-03-12T02:00:04Z |
| format | Article |
| id | doaj.art-402f59a4dffa4e95b4dafcffde87f624 |
| institution | Directory Open Access Journal |
| issn | 1178-6965 |
| language | English |
| last_indexed | 2024-03-12T02:00:04Z |
| publishDate | 2023-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Asthma and Allergy |
| spelling | doaj.art-402f59a4dffa4e95b4dafcffde87f6242023-09-07T19:14:38ZengDove Medical PressJournal of Asthma and Allergy1178-69652023-09-01Volume 1693795086471Lung Function and Asthma Clinical Control in N-ERD Patients, Three-Year Follow-Up in the Context of Real-World EvidencePavón-Romero GFFalfán-Valencia RGutiérrez-Quiroz KVDe La O-Espinoza EASerrano-Pérez NHRamírez-Jiménez FTeran LMGandhi Fernando Pavón-Romero,1 Ramcés Falfán-Valencia,2 Katia Vanessa Gutiérrez-Quiroz,1 Estivaliz Arizel De La O-Espinoza,1 Nancy Haydée Serrano-Pérez,1 Fernando Ramírez-Jiménez,1 Luis M Teran1 1Department of Immunogenetics and Allergy, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; 2Laboratory of Human Leukocyte Antigen, Instituto Nacional de Enfermedades Respiratorias, Mexico City, MexicoCorrespondence: Luis M Teran, Department of Immunogenetics and Allergy, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Tlalpan, Mexico City, 14080, Mexico, Tel +52 5557481700 exr. 5162, Email teranjlm@gmail.comPurpose: To describe the lung function and clinical control of asthma in patients with N-ERD during three years of medical follow-up using GINA guidelines.Methods: We evaluated 75 N-ERD and 68 asthma patients (AG). Clinical control, lung function, and asthma treatment were evaluated according to GINA-2014. We compared all variables at baseline and one, two, and three years after treatment.Results: At baseline, the N-ERD group had better basal lung function (LF) than the AG group (p< 0.01), and the AG group used higher doses of inhaled corticosteroids than the N-ERD group (52.4% vs 30.5%, p=0.01) and short-term oral corticosteroid (OCS) use (52.4% vs 30.5%, p< 0.01). Instead, N-ERD patients needed more use of leukotriene receptor antagonists (LTRA) (29.3% vs 5.9%, p< 0.01). This group had better clinical control than the AG group (62.1% vs 34.1%, p< 0.01). During the medical follow-up, the LF of the N-ERD group remained at normal values; however, these parameters improved in AG from one year (p< 0.01). Likewise, there was a diminished use of high doses of ICS (52.4% vs 33%, p< 0.05) and short-term OCS (67.6% vs 20.6%, p< 0.01) in asthma patients. However, N-ERD patients still needed more use of LTRAs (p< 0.02) during the study. In this context, one-third of N-ERD patients had to use a combination of two drugs to maintain this control. From the second year on, clinical control of asthma was similar in both groups (p> 0.05).Conclusion: According to GINA guidelines, only one-third of patients with N-ERD can gradually achieve adequate lung function and good asthma control with a high ICS dosage. Only a very small portion of patients will require the continued use of a second medication as an LTRA to keep their asthma under control.Keywords: N-ERD, asthma, severe asthma, corticosteroids, GINA guidelines, asthma clinical controlhttps://www.dovepress.com/lung-function-and-asthma-clinical-control-in-n-erd-patients-three-year-peer-reviewed-fulltext-article-JAAn-erdasthmasevere asthmacorticosteroidsgina guidelinesasthma clinical control |
| spellingShingle | Pavón-Romero GF Falfán-Valencia R Gutiérrez-Quiroz KV De La O-Espinoza EA Serrano-Pérez NH Ramírez-Jiménez F Teran LM Lung Function and Asthma Clinical Control in N-ERD Patients, Three-Year Follow-Up in the Context of Real-World Evidence Journal of Asthma and Allergy n-erd asthma severe asthma corticosteroids gina guidelines asthma clinical control |
| title | Lung Function and Asthma Clinical Control in N-ERD Patients, Three-Year Follow-Up in the Context of Real-World Evidence |
| title_full | Lung Function and Asthma Clinical Control in N-ERD Patients, Three-Year Follow-Up in the Context of Real-World Evidence |
| title_fullStr | Lung Function and Asthma Clinical Control in N-ERD Patients, Three-Year Follow-Up in the Context of Real-World Evidence |
| title_full_unstemmed | Lung Function and Asthma Clinical Control in N-ERD Patients, Three-Year Follow-Up in the Context of Real-World Evidence |
| title_short | Lung Function and Asthma Clinical Control in N-ERD Patients, Three-Year Follow-Up in the Context of Real-World Evidence |
| title_sort | lung function and asthma clinical control in n erd patients three year follow up in the context of real world evidence |
| topic | n-erd asthma severe asthma corticosteroids gina guidelines asthma clinical control |
| url | https://www.dovepress.com/lung-function-and-asthma-clinical-control-in-n-erd-patients-three-year-peer-reviewed-fulltext-article-JAA |
| work_keys_str_mv | AT pavonromerogf lungfunctionandasthmaclinicalcontrolinnerdpatientsthreeyearfollowupinthecontextofrealworldevidence AT falfanvalenciar lungfunctionandasthmaclinicalcontrolinnerdpatientsthreeyearfollowupinthecontextofrealworldevidence AT gutierrezquirozkv lungfunctionandasthmaclinicalcontrolinnerdpatientsthreeyearfollowupinthecontextofrealworldevidence AT delaoespinozaea lungfunctionandasthmaclinicalcontrolinnerdpatientsthreeyearfollowupinthecontextofrealworldevidence AT serranopereznh lungfunctionandasthmaclinicalcontrolinnerdpatientsthreeyearfollowupinthecontextofrealworldevidence AT ramirezjimenezf lungfunctionandasthmaclinicalcontrolinnerdpatientsthreeyearfollowupinthecontextofrealworldevidence AT teranlm lungfunctionandasthmaclinicalcontrolinnerdpatientsthreeyearfollowupinthecontextofrealworldevidence |